You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

Authors

  • Abdul Rafeh Naqash Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USAHematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA PubMed articlesGoogle scholar articles
  • Justin D McCallen Department of Internal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USABrody School of Medicine, East Carolina University, Greenville, NC, USA PubMed articlesGoogle scholar articles
  • Emma Mi Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK PubMed articlesGoogle scholar articles
  • Sanna Iivanainen Oncology and Radiation Department, Oulu University Hospital, University of Oulu, MRC Oulu, Oulu, Finland PubMed articlesGoogle scholar articles
  • Mona A Marie Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA PubMed articlesGoogle scholar articles
  • Daria Gramenitskaya Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK PubMed articlesGoogle scholar articles
  • James Clark Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK PubMed articlesGoogle scholar articles
  • Jussi Pekka Koivunen Oncology and Radiation Department, Oulu University Hospital, University of Oulu, MRC Oulu, Oulu, Finland PubMed articlesGoogle scholar articles
  • Shravanti Macherla Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA PubMed articlesGoogle scholar articles
  • Sweta Jonnalagadda Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA PubMed articlesGoogle scholar articles
  • Shanker Polsani Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA PubMed articlesGoogle scholar articles
  • Rahim Ali Jiwani Department of Internal Medicine, East Carolina University, Greenville, NC, USA PubMed articlesGoogle scholar articles
  • Maida Hafiz Division of Pulmonary Critical Care, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USADivision of Pulmonary and Critical Care, East Carolina University, Greenville, NC, USA PubMed articlesGoogle scholar articles
  • Mahvish Muzaffar Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA PubMed articlesGoogle scholar articles
  • Leonardo Brunetti Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Roma, Italy, Italy PubMed articlesGoogle scholar articles
  • Chipman R G Stroud Genentech, South San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Paul R Walker Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USACirculogene, Birmingham, Alabama, USA PubMed articlesGoogle scholar articles
  • Kun Wang Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Youngmin Chung Department of Artificial Intelligence, Sungkyunkwan University, Suwon, Reuplic of Korea PubMed articlesGoogle scholar articles
  • Eytan Ruppin Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Se-Hoon Lee Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center School of Medicine, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Li V Yang Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA PubMed articlesGoogle scholar articles
  • David J Pinato Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UKDivision of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy PubMed articlesGoogle scholar articles
  • Joo Sang Lee Department of Artificial Intelligence, Sungkyunkwan University, Suwon, Reuplic of KoreaDepartment of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Republic of KoreaDepartment of Digital Health, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea PubMed articlesGoogle scholar articles
  • Alessio Cortellini Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UKOperative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Roma, Italy, Italy PubMed articlesGoogle scholar articles

Citation

Naqash AR, McCallen JD, Mi E, et al
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
Journal for ImmunoTherapy of Cancer 2023;11:e007310. doi: 10.1136/jitc-2023-007310
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.